Ionis’s Zanvastro, an antisense drug that dials down a toxic protein, stabilized walking in patients with the ultra-rare, progressive neurological disorder — which until now had no disease-modifying therapy.
The company helps patients steer through cancer care — and is now building a broader oncology group backed by Humana, CVS and JPMorgan’s Morgan Health.
The GLP-1 drug behind Ozempic and Wegovy lengthened lifespan and improved muscle, memory and inflammation in old mice — and the benefits weren’t explained by calorie cutting alone.
In a Phase 3 trial, pulmonary-artery denervation cut clinical worsening roughly in half for patients whose heart failure had driven up pressure in the lungs’ arteries.
Harvard researchers converted human pancreatic duct cells into insulin-making “beta-like” cells by disabling a single gene — a potential new route to replacing what diabetes destroys.
After a bruising regulatory saga, the company submitted AMT-130 — a one-time, brain-delivered gene therapy that slowed disease progression over three years — for accelerated approval.
A decade-long study found that obesity imprints durable molecular marks on immune cells that can persist for years after people slim down, which may help explain lingering health risks.
There’s no approved drug for celiac disease — only a strict gluten-free diet. Teva’s experimental TEV-408 significantly reduced gluten-triggered intestinal damage in a mid-stage study.
Groups representing pediatricians, family doctors and OB-GYNs released their own respiratory-season recommendations — including an extended RSV-vaccine window for pregnancy.
The deal buys rights to an early-stage “tri-specific” antibody built to hit B cells — drivers of many autoimmune conditions — from multiple angles at once.
Takotsubo syndrome mimics a heart attack but involves no blocked arteries. A new score using blood markers and sex identified it with nearly 90% accuracy — before invasive testing.
Unlike today’s flu shots, GSK’s mRNA vaccine aims at two viral surface proteins instead of one — and it’s heading into Phase 3 after encouraging immune responses.